Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2015 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
LEGEND BIOTECH CORPORATION | 12 | Q2 2024 | 25.6% |
FATE THERAPEUTICS, INC. | 12 | Q2 2024 | 24.8% |
PROTAGONIST THERAPEUTICS INC. | 12 | Q2 2024 | 21.2% |
CVRX, INC. | 12 | Q2 2024 | 19.5% |
MEIRAGTX HOLDINGS PLC | 12 | Q2 2024 | 13.9% |
Arrowhead Pharmaceuticals, Inc. | 12 | Q2 2024 | 24.6% |
PROCEPT BIOROBOTICS CORPORATION | 12 | Q2 2024 | 10.5% |
ADICET BIO, INC. | 12 | Q2 2024 | 3.0% |
VOR BIOPHARMA, INC. | 12 | Q2 2024 | 2.1% |
ALDEYRA THERAPEUTICS, INC. | 12 | Q2 2024 | 1.3% |
View JOHNSON & JOHNSON's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Kenvue Inc. | May 20, 2024 | ? | ? |
Contineum Therapeutics, Inc. | April 10, 2024 | 1,979,173 | 10.7% |
BiomX Inc. | February 02, 2024 | 2,113,402 | 4.6% |
CVRx, Inc. | February 02, 2024 | 4,109,336 | 19.2% |
Nanobiotix S.A. | February 02, 2024 | 5,623,816 | 11.9% |
Fusion Pharmaceuticals Inc. | January 27, 2023 | 3,670,516 | 8.2% |
Protagonist Therapeutics, Inc | January 11, 2023 | 2,449,183 | 5.0% |
MeiraGTx Holdings plc | November 14, 2022 | 6,641,064 | 13.7% |
PhaseBio Pharmaceuticals Inc | February 01, 2022 | 1,607,044 | 3.3% |
Provention Bio, Inc. | January 17, 2020 | 1,124,973 | 2.4% |
View JOHNSON & JOHNSON's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
8-K | 2024-09-20 |
4 | 2024-09-12 |
4 | 2024-09-12 |
8-K | 2024-09-10 |
4 | 2024-09-03 |
144 | 2024-08-30 |
N-PX | 2024-08-29 |
8-K | 2024-08-26 |
13F-HR | 2024-08-09 |
SC 13G | 2024-07-30 |
View JOHNSON & JOHNSON's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.